GlassScriptPhysician profile
Marilee J Mccleerey
NPI 1710577283
$1,928.91
in general payments reported to CMS, 2019-2025
21 companies · $293 in 2025
The $293 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $173 · 2022: $299 · 2023: $553 · 2024: $611 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,456.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $315.75 | 2022-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $310.19 | 2021-2024 | Spravato |
| Supernus Pharmaceuticals, INC. | $193.29 | 2021-2024 | Qelbree |
| Axsome Therapeutics, INC. | $126.64 | 2024-2025 | Auvelity, Sunosi |
| Tris Pharma INC | $120.84 | 2022-2025 | Dyanavel Xr |
| Otsuka America Pharmaceutical, INC. | $117.26 | 2022-2025 | Rexulti |
| Lundbeck LLC | $106.71 | 2022-2024 | Brintellix, Rexulti |
| Abbvie INC. | $92.20 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $88.44 | 2023-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $85.75 | 2022 | |
| Neurocrine Biosciences, INC. | $76.24 | 2023-2024 | Ingrezza |
| Harmony Biosciences LLC | $56.52 | 2023-2024 | Wakix |
| Collegium Pharmaceutical, INC. | $49.82 | 2025 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $42.67 | 2024-2025 | Caplyta |
| Neos Therapeutics, LP | $33.06 | 2023-2024 | Adzenys Xr-Odt |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $29.33 | 2023-2025 | Xelstrym |
| Teva Pharmaceuticals USA, INC. | $26.25 | 2023 | Austedo, Austedo Xr |
| Vertical Pharmaceuticals, LLC | $16.04 | 2025 | Relexxii |
| Idorsia Pharmaceuticals US INC | $14.39 | 2023 | Quviviq |
| Janssen Scientific Affairs, LLC | $14.29 | 2025 | Spravato |
| Ironshore Pharmaceuticals INC. | $13.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marilee Mccleerey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.